BET Protein Inhibition for Pulmonary Arterial Hypertension

Mar 14, 2022

1 min read

Updated: Nov 7, 2024

This pilot study added apabetalone to people's PAH therapy twice daily for 16 weeks to see if a future clinical trial evaluating bromodomain inhibition in pulmonary arterial hypertension might be feasible. They also aimed to provide preliminary evidence that apabetalone may be safe and effective in PAH.

Read the original journal article

Recent Posts

Frequent imaging of children with PH may lead to high radiation doses

A 41-study review of children with non-cancer chronic diseases looked at how much radiation they were exposed to during their relatively frequent medical imaging. Children with PH were included. The r

What affects physical activity for people with PH?

A UK study examined the factors that affected physical activity participation among people with pulmonary hypertension (PH). They found four themes: fear of breathlessness; lack of motivation and a de

Why men with systemic sclerosis-associated PAH fare worse

Men with systemic sclerosis and pulmonary arterial hypertension (PAH) tend to have more heart-related complications and lower survival rates. Differences in the effects of hormones such as estrogen an

Comments